Back to Search
Start Over
Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin-treated diabetic dogs.
Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin-treated diabetic dogs.
- Source :
-
Journal of veterinary internal medicine [J Vet Intern Med] 2024 May-Jun; Vol. 38 (3), pp. 1353-1358. Date of Electronic Publication: 2024 Mar 25. - Publication Year :
- 2024
-
Abstract
- Background: The utility of sodium-glucose cotransporter 2 inhibitors (SGLT2i) has not been reported in insulin-treated diabetic dogs.<br />Hypothesis: Canagliflozin, a PO-administered SGLT2i, decreases interstitial glucose concentration (IG) in insulin-treated diabetic dogs.<br />Animals: Five insulin-treated diabetic dogs.<br />Methods: Uncontrolled open label longitudinal study. Canagliflozin (2-4 mg/kg/day PO) was added to an unchanged insulin dose for 7 days. Fractional excretion of glucose was calculated by dividing the product of urine glucose and serum creatinine concentrations by the product of serum glucose and urine creatinine concentrations. Hypoglycemia was defined as IG <60 mg/dL.<br />Results: Median IG in 2869 measurements obtained while dogs were treated with insulin and canagliflozin was 87 mg/dL (range, 40-500 mg/dL) and was significantly lower than median IG in 1426 measurements obtained while dogs were treated with insulin alone (212 mg/dL; range, 41-500 mg/dL; P < .001). Median fractional excretion of glucose when dogs were treated with insulin and canagliflozin was 1.1% (range, 0.9%-2.0%), significantly higher than when dogs were treated with insulin alone (0.3%; range, 0.01%-1.0%; P = .04). The frequency of hypoglycemia was higher in dogs treated with insulin and canagliflozin (544 of 2869 IG measurements, 19%) compared with the frequency of hypoglycemia in dogs treated with insulin alone (52 of 1426 IG measurements, 4%; P < .001).<br />Conclusions and Clinical Importance: Canagliflozin may have a role in improving glycemic control in insulin-treated diabetic dogs, but the dose of insulin should be decreased when adding canagliflozin to insulin treatment.<br /> (© 2024 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)
- Subjects :
- Animals
Dogs
Female
Male
Blood Glucose analysis
Blood Glucose drug effects
Diabetes Mellitus veterinary
Diabetes Mellitus drug therapy
Hypoglycemia veterinary
Hypoglycemia chemically induced
Hypoglycemic Agents therapeutic use
Hypoglycemic Agents pharmacology
Hypoglycemic Agents administration & dosage
Longitudinal Studies
Canagliflozin therapeutic use
Canagliflozin pharmacology
Dog Diseases drug therapy
Glucose metabolism
Insulin therapeutic use
Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Sodium-Glucose Transporter 2 Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1939-1676
- Volume :
- 38
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of veterinary internal medicine
- Publication Type :
- Academic Journal
- Accession number :
- 38528660
- Full Text :
- https://doi.org/10.1111/jvim.17053